Allergy Shots for Mold Allergy: Why Only Alternaria Has the Evidence

Allergy shots work for mold allergy caused by Alternaria alternata, the only fungal species with high-quality randomized controlled trial evidence. Kuna et al.'s 3-year double-blind trial showed 63.5% CSMS reduction by year 3, and Tabar et al.'s 2019 multicenter trial confirmed dose-dependent CSMS reduction at 0.37 mcg Alt a 1 maintenance dosing. For molds other than Alternaria — including Aspergillus, Penicillium, and Cladosporium — the evidence base is insufficient to support immunotherapy under current AAAAI/ACAAI or EAACI practice parameters. If you have mold allergy, confirming which specific mold species you are sensitized to through IgE testing is the essential step before any immunotherapy decision.

Alternaria alternata differs from other clinically relevant molds in two important ways. First, it has more and higher-quality clinical trial evidence than any other mold species for immunotherapy. Second, Alternaria sensitization carries significant clinical risk beyond symptom burden — it is an independent risk factor for severe asthma exacerbations. This combination of available evidence and clinical severity makes Alternaria the mold for which immunotherapy investment is most clearly justified. In contrast, Cladosporium has limited data with higher systemic reaction rates; Aspergillus immunotherapy is complicated by cross-reactivity concerns between Aspergillus and Alternaria, and lack of efficacy data; and Penicillium, Helminthosporium, and other common molds have essentially no robust SCIT trial data supporting their use.

A critical and underappreciated reason mold allergy shots may not work is extract quality. Vailes et al. (2001) found that many commercial Alternaria and Aspergillus extracts contained no detectable major allergen (Alt a 1 or Asp f 1) by ELISA testing. This means patients could complete months or years of injections without receiving any therapeutically active allergen. This extract quality problem is less severe for standardized extracts like cat, grass, dust mites, and ragweed, but it is a major practical concern for mold extracts, which are among the least standardized in US clinical use. Before starting mold SCIT, patients should ask their allergist about extract quality and whether the preparation contains verified major allergen content.

Alternaria sensitization carries clinical risks beyond typical seasonal allergy symptoms. It is an established independent risk factor for severe asthma exacerbations — meaning patients with documented Alternaria sensitization and asthma have higher rates of hospitalization and life-threatening asthma attacks compared to patients with asthma who are not sensitized to Alternaria. This elevated risk makes immunotherapy particularly relevant for Alternaria-sensitized asthmatic patients — not just for symptom relief, but for reducing the asthma exacerbation risk associated with seasonal Alternaria exposure. If you have asthma and mold allergy, discussing allergen testing and immunotherapy options with your allergist is especially important.

Environmental controls are emphasized more strongly for mold allergy than for most other allergens, particularly when the evidence for immunotherapy is limited to a single species. Key measures include moisture control (indoor humidity below 50%, addressing water damage and leaks promptly), using HEPA air filtration in sleeping areas, avoiding activities with high outdoor mold exposure (raking leaves, mowing damp grass, composting), wearing an N95 mask during high-mold-exposure outdoor tasks, and regularly cleaning refrigerator drip pans, shower areas, and windowsills where mold grows indoors. Mold counts are highest outdoors from late summer through fall in most temperate regions. Even for patients receiving Alternaria SCIT, environmental controls are recommended alongside immunotherapy to reduce the overall allergen load.